This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Imatinib Mesylate in Polycythemia Vera

This study has been completed.
Information provided by (Responsible Party):
Niguarda Hospital Identifier:
First received: January 31, 2007
Last updated: October 7, 2014
Last verified: October 2014

The purpose of this study is to determine the activity of Glivec 400 mg po daily, as single agent, in inducing a haematological response in Polycythemia Vera.

The patients will be asked to have additional bone marrow and blood samples collected: these samples will be used to evaluate how the disease is responding to the drug.

Condition Intervention Phase
Polycythemia Vera Drug: Imatinib Mesylate Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Glivec (Imatinib Mesylate) in the Treatment of Polycythemia Vera

Resource links provided by NLM:

Further study details as provided by Niguarda Hospital:

Primary Outcome Measures:
  • Reduction of Haematocrit to less than 45%. [ Time Frame: 6-12 months ]

Secondary Outcome Measures:
  • Response duration [ Time Frame: 6-12 months ]
  • Safety profile [ Time Frame: 6-12 months ]
  • Reduction in platelet count and spleen size [ Time Frame: 6-12 months ]
  • Reduction of incidence phlebotomies. [ Time Frame: 6-12 months ]
  • Symptoms improvement in patients. [ Time Frame: 6-12 months ]

Enrollment: 9
Study Start Date: February 2007
Study Completion Date: September 2012
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Imatinib Mesylate
400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)
Drug: Imatinib Mesylate
400 mg/die for 6 months

Detailed Description:
Hematocrit <45% in men or <42% in women at 1°evaluation within 6 months In case of complete or partial responsiveness, experimental treatment will be continued until 12 months In case of disease progression or treatment failure, experimental drug will be withdrawn and patient will be out of the study

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Polycythemia Vera requiring treatment with either phlebotomy or Hydroxyurea
  • Age >18 years
  • Signed written informed consent form

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Creatinine >3 max NV
  • Bilirubin >3 max NV
  • AST/ALT >3 max NV
  • Concomitant and severe psychiatric disorder
  • Concomitant neoplastic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00430066

Sponsors and Collaborators
Niguarda Hospital
Study Director: Enrica Morra, MD Divisione di Ematologia - Ospedale Niguarda Ca' Granda
  More Information

Responsible Party: Niguarda Hospital Identifier: NCT00430066     History of Changes
Other Study ID Numbers: CSTI571POLIVERA
Study First Received: January 31, 2007
Last Updated: October 7, 2014

Additional relevant MeSH terms:
Polycythemia Vera
Hematologic Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017